(+)-(R)-1-(pyridin-4-yl)-1,3-propanediol | 329325-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (+)-(R)-1-(pyridin-4-yl)-1,3-propanediol
• 英文别名: pyridinediol；(R)-1-(pyridin-4-yl)propane-1,3-diol；R-(+)-1-(4-pyridyl)-1,3-propane diol；(1R)-1-pyridin-4-ylpropane-1,3-diol
• CAS: 329325-42-0
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: QDPWSASGSYTONB-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-(R)-1-(pyridin-4-yl)-1,3-propanediol 在 吡啶 、 叔丁基氯化镁 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 40.0h， 生成 4-氨基-1-[5-O-[(2R,4S)-2-氧代-4-(4-吡啶基)-1,3,2-二氧磷杂环己烷-2-基]-BETA-D-呋喃阿拉伯糖基]-2(1H)-嘧啶酮
  参考文献：
  名称：

  Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma

  摘要：

  Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating > 19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and > 12-fold higher araCTP levels in the liver than in the bone marrow, representing a > 120-fold and > 28-fold improvement, respectively, over araC administration.

  DOI：

  10.1021/jm0607449
• 作为产物：
  描述：

  3-羟基-3-(吡啶-4-基)丙酸乙酯 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 (+)-(R)-1-(pyridin-4-yl)-1,3-propanediol
  参考文献：
  名称：

  Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma

  摘要：

  Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating > 19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and > 12-fold higher araCTP levels in the liver than in the bone marrow, representing a > 120-fold and > 28-fold improvement, respectively, over araC administration.

  DOI：

  10.1021/jm0607449

文献信息

• Chiral Primary Amine Catalyzed Asymmetric Direct Cross-Aldol Reaction of Acetaldehyde
  作者：Shenshen Hu、Long Zhang、Jiuyuan Li、Sanzhong Luo、Jin-Pei Cheng

  DOI：10.1002/ejoc.201100267

  日期：2011.6

  The first primary aminocatalytic direct cross-aldol reaction of acetaldehyde is presented. Among the various vicinal diamines screened, the L-tert-leucine derivative 1c in conjunction with (H4SiW12O40)0.25 was identified as the optimal catalyst; good catalytic activity (up to 99 % yield in 4 h), and high enantioselectivities (up to 92 % ee) were achieved for a range of donors, including aromatic aldehydes

  介绍了乙醛的第一个伯氨基催化直接交叉羟醛反应。在筛选的各种邻二胺中，L-叔亮氨酸衍生物1c与(H4SiW12O40)0.25结合被确定为最佳催化剂；对一系列供体（包括芳香醛和靛红衍生物）实现了良好的催化活性（4 小时内高达 99% 的产率）和高对映选择性（高达 92% ee）。乙醛水溶液和三聚乙醛可以方便地应用于该系统。
• Novel cytarabine monophosphate prodrugs
  申请人：——

  公开号：US20040092476A1

  公开（公告）日：2004-05-13

  Compounds of Formula I, their preparation and uses are described: 1 wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.

  式I的化合物，其制备和用途如下所述： 其中： M和V相对于彼此为顺式，MH为紫杉醇； 所述紫杉醇的5′氧原子连接到磷； V为4-吡啶基； 以及其药用可接受的前药和盐。
• Novel 2'-C-methyl nucleoside derivatives
  申请人：Reddy Raja K.

  公开号：US20050182252A1

  公开（公告）日：2005-08-18

  Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

  化合物I的配方、立体异构体以及其药用可接受的盐或前药，它们的制备以及它们用于治疗丙型肝炎病毒感染的用途被描述：
• 阿糖胞苷前药有关物质及其应用
  申请人：西安新通药物研究股份有限公司

  公开号：CN113621008A

  公开（公告）日：2021-11-09

  本发明提供了分离的化合物，其为阿糖胞苷前药有关物质。本发明还提供了所述化合物的应用，用于制备阿糖胞苷前药或包含阿糖胞苷前药的组合物。
• A Diarylprolinol in an Asymmetric, Catalytic, and Direct Crossed-Aldol Reaction of Acetaldehyde
  作者：Yujiro Hayashi、Takahiko Itoh、Seiji Aratake、Hayato Ishikawa

  DOI：10.1002/anie.200704870

  日期：2008.2.28